emamectin-benzoate and teflubenzuron

Veterinary medicinal products (VMPs) are widely used within the fish farming industry to control sea lice infestations. There is concern that wild and farmed mussels in the vicinity to these fish farms may be exposed and subsequently bioaccumulate these chemicals, which could pose a threat to human health. To understand the fate of these chemicals in the environment, controlled laboratory exposures were performed to establish the uptake and depuration of selected VMPs in the blue mussel (Mytilus edulis). The VMPs included teflubenzuron, emamectin benzoate and deltamethrin. The effects of salinity on the bioaccumulation of teflubenzuron were also investigated to see whether mussels in brackish waters exhibit different bioaccumulation dynamics. Salinity had no significant effect on the uptake or depuration curves for teflubenzuron down to 15‰. The uptake rate constants (k

Topics: Animals; Benzamides; Ivermectin; Kinetics; Mytilus edulis; Nitriles; Pyrethrins; Veterinary Drugs; Water Pollutants, Chemical

Emamectin benzoate is used as an in-feed treatment for the control of sea lice parasites in all of the main farmed Atlantic salmon (Salmo salar) facilities worldwide (Norway, Chile, Scotland and Canada). Investigations into its effect on non-target benthic fauna resulting from its excretion from farmed fish and uneaten feed have been limited. This paper presents the findings from a study that intended to assess the impact of emamectin benzoate on benthic fauna using a new low detection method for emamectin benzoate. Eight fish farms in the Shetland Isles, Scotland were surveyed, with sediment sampled along transects radiating from the farms analysed for benthic ecology, sediment chemistry and sediment veterinary medicine residues (analysed for emamectin benzoate and teflubenzuron). Canonical Correspondence Analysis (CCA) and Generalised Linear Mixed Modelling (GLMM) were used to assess which environmental parameters observed during the survey had the biggest effect on benthic community composition and abundance, and more specifically crustacean abundance and richness. Emamectin benzoate was found in 97% of samples, demonstrating widespread dispersion in the sediments sampled. The CCA showed that species composition was predominantly ordinated along a gradient of particle size, with a secondary axis dominated by a change in emamectin benzoate and organic carbon enrichment. Peaks in abundance of crustacean species were predicted to be organised along a gradient of emamectin benzoate concentration. The GLMM corroborated this by showing that emamectin benzoate had the strongest negative effect on total crustacean abundance and species richness, though there was some degree of collinearity with organic carbon, that had a smaller effect. Overall, this study shows that, following its use as an in-feed treatment for sea lice, emamectin benzoate residues are more widely distributed in the benthic environment than previously thought, and have a statistically significant effect on benthic ecology at the concentrations observed in this study.

Topics: Animals; Antiparasitic Agents; Aquatic Organisms; Benzamides; Biota; Copepoda; Environmental Monitoring; Fisheries; Ivermectin; Scotland; Seawater

Growth of the aquaculture industry has triggered the need for research into the potential environmental impact of chemicals used by salmon farms to control diseases. In this study, the antiparasitic pesticides emamectin benzoate (EB), diflubenzuron (DI), teflubenzuron (TE), and cypermethrin (CP) were measured in sediments near salmon cages in southern Chile. Concentrations for EB were between 2.2 and 14.6ngg

Topics: Animals; Antiparasitic Agents; Aquaculture; Benzamides; Chile; Diflubenzuron; Geologic Sediments; Ivermectin; Pesticides; Pyrethrins; Salmon

The sea louse is the most economically and environmentally serious ectoparasite of marine salmonids. Sea lice have been largely controlled by treatment with a variety of medicines. In order to understand the sustainability of medicine usage, an analysis of sea louse treatment data has been carried out for all Scottish salmon farms from 2005 to 2011.. Overall, there was an increase from 0.156 to 0.282 treatments month(-1) ; treatments could involve one or multiple agents. This increase was mostly in bath treatments (cypermethrin in 2007, largely replaced by deltamethrin and azamethiphos in 2008). Treatments using in-feed treatments (emamectin benzoate and teflubenzuron) increased only slowly. Treatments involving more than one medicine in a single month also increased, as did the probability of follow-up treatments. Treatments were seasonal, with peaks of in-feed treatments in March and August and bath treatments more frequent between August and December.. Frequency of sea louse treatment increased substantially, with an increase in multiagent and follow-up treatments. This increase in treatment activity is expensive to the industry and increases exposure of the neighbouring environment. This indicates that earlier louse control practices were not sustainable and so adapted.

Topics: Animals; Antiparasitic Agents; Aquaculture; Benzamides; Copepoda; Fish Diseases; Ivermectin; Nitriles; Pyrethrins; Salmon; Seasons

Diflubenzuron and teflubenzuron are benzoylureas that are used in aquaculture to control sea lice. Flubenzurons have low toxicity to many marine species such as fish and algae but by their nature are likely to have significant adverse effects on nontarget species such as crustaceans and amphipods. Although the exact mechanism of toxicity is not known, these compounds are thought to inhibit the production of the enzyme chitin synthase during molting of immature stages of arthropods. These chitin synthesis inhibitors are effective against the larval and pre-adult life stages of sea lice. Due to their low solubility and results of recent monitoring studies conducted in Norway, the sediment compartment is considered the most likely reservoir for these compounds and possible remobilization from the sediment to benthic crustaceans could be of importance. For this reason, the epibenthic copepod Tisbe battagliai was selected for investigations into the acute and developmental effects of these compounds. For comparative purposes, azamethiphos was investigated to identify differences in sensitivity and act as a negative control for developmental effects at environmentally relevant concentrations. Standard acute studies with adult copepods showed little or no acute toxicity at milligrams per liter levels with the flubenzurons, whereas a naupliar developmental test demonstrated that environmentally relevant concentrations (e.g., nanograms per liter) caused a complete cessation of molting and finally death in the exposed copepods.

Topics: Animals; Aquaculture; Benzamides; Copepoda; Diflubenzuron; Disaccharides; Ivermectin; Life Cycle Stages; Organothiophosphates; Pesticides; Toxicity Tests, Acute; Veterinary Drugs; Water Pollutants, Chemical

Aquaculture production is an important industry in many countries and there has been a growth in the use of medicines to ensure the health and cost effectiveness of the industry. This study focused on the inputs of sea lice medication to the marine environment. Diflubenzuron, teflubenzuron, emamectin benzoate, cypermethrin, and deltamethrin were measured in water, sediment, and biota samples in the vicinity of five aquaculture locations along the Norwegian coast. Deltamethrin and cypermethrin were not detected above the limits of detection in any samples. Diflubenzuron, teflubenzuron, and emamectin benzoate were detected, and the data was compared the UK Environmental Quality Standards. The concentrations of emamectin benzoate detected in sediments exceed the environmental quality standard (EQS) on 5 occasions in this study. The EQS for teflubenzuron in sediment was exceeded in 67% of the samples and exceeded for diflubenzuron in 40% of the water samples collected. A crude assessment of the concentrations detected in the shrimp collected from one location and the levels at which chronic effects are seen in shrimp would suggest that there is a potential risk to shrimp. It would also be reasonable to extrapolate this to any species that undergoes moulting during its life cycle.

Topics: Animals; Antiparasitic Agents; Aquaculture; Aquatic Organisms; Benzamides; Biota; Crustacea; Diflubenzuron; Environmental Monitoring; Ivermectin; Nitriles; Norway; Pyrethrins; Reference Standards; Risk Assessment; Risk Factors; Water; Water Pollutants, Chemical; Water Supply

Four commercial salmon farms on the West coast of Norway were recruited to a programme of field trials in which the efficacy of SLICE (0.2% emamectin benzoate; Schering-Plough Animal Health) was compared with a commercially available product, EKTOBANN (teflubenzuron 2 g kg(-1); Skretting A/S) in treating natural sea lice Lepeophtheirus salmonis infections in Atlantic salmon Salmo salmar L. At each test site, 3 fish pens were treated with each product. In total, nearly 1.2 million first-year-class fish were included in the trial, of which approximately 561,000 received emamectin benzoate at a dosage of 50 microg kg(-1) body wt d(-1), while approximately 610,000 received teflubenzuron at a dosage of 10 mg kg(-1) body wt d(-1). Medicated feed was provided at 0.5% body wt d(-1) over 7 consecutive days. Feed containing emamectin benzoate was generally well accepted by the fish and no problems were encountered in feeding the medicated diet at the desired dose. Lice numbers were counted 2 d before and 1, 7, 14 and 21 d after commencement of treatment. While treatment with both substances rapidly reduced lice numbers, pens treated with emamectin benzoate were found to harbour significantly fewer lice 14 and 21 d post-treatment. Twenty-one days following treatment with emamectin benzoate the lice abundance was reduced on average by 94%. Limited sampling outside the main study period indicated that emamectin benzoate protects against sea-lice infestation over longer periods.

Topics: Administration, Oral; Animals; Aquaculture; Benzamides; Crustacea; Ectoparasitic Infestations; Fish Diseases; Insecticides; Ivermectin; Norway; Salmo salar; Treatment Outcome